文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

较慢与较快静脉液体负荷速度对危重患者死亡率的影响:BaSICS随机临床试验

Effect of Slower vs Faster Intravenous Fluid Bolus Rates on Mortality in Critically Ill Patients: The BaSICS Randomized Clinical Trial.
PubMed 文献 · JAMA · 2021-01-01
一句话结论在ICU需要液体负荷的患者中,较慢速度(333 mL/h)与较快速度(999 mL/h)相比未降低90天死亡率,不支持使用较慢输注速度。

BaSICS是在巴西75个ICU开展的非盲析因随机临床试验,纳入11 052例需要至少1次液体负荷且具有1项不良结局危险因素的患者,随机接受较慢速度(333 mL/h)或对照速度(999 mL/h)液体负荷,同时析因随机接受平衡液或0.9%氯化钠。共分析10 520例(95.2%),较慢速度组第1天平均输注1162 mL,对照组1252 mL。90天时较慢速度组5276例中1406例(26.6%)死亡,对照组5244例中1414例(27.0%)死亡(校正HR 1.03;95%CI 0.96-1.11;P=0.46),液体类型与输注速度无显著交互作用(P=0.98)。结论认为较慢输注速度未降低90天死亡率,不支持使用较慢输注速度。

要点

  • 在需要液体负荷的ICU患者中,较慢速度333 mL/h与对照速度999 mL/h相比,90天死亡率无显著差异(26.6% vs 27.0%;校正HR 1.03;95%CI 0.96-1.11;P=0.46)。
  • 该试验在巴西75个ICU进行,纳入11 052例需要至少1次液体负荷且具有1项不良结局危险因素的患者,共分析10 520例(95.2%)。
  • 较慢速度组第1天平均输注1162 mL,对照组1252 mL。
  • 液体类型(平衡液或0.9%氯化钠)与输注速度之间无显著交互作用(P=0.98)。
  • 作者结论认为,这些发现不支持使用较慢的输注速度。

适用人群与场景

  • 纳入:在ICU需要至少1次液体负荷且具有1项不良结局危险因素的患者。
  • 场景:巴西75个ICU。

处置流程与药物剂量

  • 较慢速度组:液体负荷以333 mL/h输注。
  • 对照组:液体负荷以999 mL/h输注。
  • 所有患者同时按析因设计随机接受平衡液或0.9%氯化钠。

研究设计与关键结果

  • 研究类型:非盲析因随机临床试验,在巴西75个ICU进行,2017年5月29日至2020年3月2日随机,随访至2020年10月29日。
  • 样本量:随机11 052例,分析10 520例(95.2%);较慢速度组5538例,对照组5514例随机。
  • 人群特征:平均年龄61.1岁(SD 17.0),44.2%为女性。
  • 干预与对照:较慢速度333 mL/h vs 对照速度999 mL/h。
  • 主要终点:90天死亡率,较慢速度组5276例中1406例(26.6%)死亡 vs 对照组5244例中1414例(27.0%)死亡(校正HR 1.03;95%CI 0.96-1.11;P=0.46)。
  • 关键次要终点:液体类型与输注速度无显著交互作用(P=0.98)。
  • 第1天平均输注量:较慢速度组1162 mL vs 对照组1252 mL。

证据类型、等级与局限

  • 证据类型:随机临床试验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者结论认为,在ICU需要液体负荷的患者中,较慢输注速度与较快速度相比未降低90天死亡率,这些发现不支持使用较慢的输注速度。

指南或共识出处

  • BaSICS随机临床试验(NCT02875873),发表于JAMA。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Slower intravenous fluid infusion rates could reduce the formation of tissue edema and organ dysfunction in critically ill patients; however, there are no data to support different infusion rates during fluid challenges for important outcomes such as mortality.

OBJECTIVE: To determine the effect of a slower infusion rate vs control infusion rate on 90-day survival in patients in the intensive care unit (ICU).

DESIGN, SETTING, AND PARTICIPANTS: Unblinded randomized factorial clinical trial in 75 ICUs in Brazil, involving 11 052 patients requiring at least 1 fluid challenge and with 1 risk factor for worse outcomes were randomized from May 29, 2017, to March 2, 2020. Follow-up was concluded on October 29, 2020. Patients were randomized to 2 different infusion rates (reported in this article) and 2 different fluid types (balanced fluids or saline, reported separately).

INTERVENTIONS: Patients were randomized to receive fluid challenges at 2 different infusion rates; 5538 to the slower rate (333 mL/h) and 5514 to the control group (999 mL/h). Patients were also randomized to receive balanced solution or 0.9% saline using a factorial design.

MAIN OUTCOMES AND MEASURES: The primary end point was 90-day survival.

RESULTS: Of all randomized patients, 10 520 (95.2%) were analyzed (mean age, 61.1 years [SD, 17.0 years]; 44.2% were women) after excluding duplicates and consent withdrawals. Patients assigned to the slower rate received a mean of 1162 mL on the first day vs 1252 mL for the control group. By day 90, 1406 of 5276 patients (26.6%) in the slower rate group had died vs 1414 of 5244 (27.0%) in the control group (adjusted hazard ratio, 1.03; 95% CI, 0.96-1.11; P = .46). There was no significant interaction between fluid type and infusion rate (P = .98).

CONCLUSIONS AND RELEVANCE: Among patients in the intensive care unit requiring fluid challenges, infusing at a slower rate compared with a faster rate did not reduce 90-day mortality. These findings do not support the use of a slower infusion rate.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02875873.

来源:JAMA,查看原文。版权归原作者所有。

参考来源

  1. Zampieri FG, Machado FR, Biondi RS, et al. Effect of Slower vs Faster Intravenous Fluid Bolus Rates on Mortality in Critically Ill Patients: The BaSICS Randomized Clinical Trial. JAMA. 2021. PMID: 34547081. doi:10.1001/jama.2021.11444

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。